{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:52:22Z","timestamp":1771383142704,"version":"3.50.1"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Eumycetoma, a chronic subcutaneous mycosis, responds poorly to the available antifungal treatments and patients often require extensive surgical resection or amputation of the affected limb. More effective treatments are needed for eumycetoma. This article will describe some of the approaches being used to develop and evaluate new treatments for eumycetoma, summarise the latest developments and discuss the challenges that lie ahead.<\/jats:p>","DOI":"10.3389\/fphar.2023.1165273","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T05:13:45Z","timestamp":1684386825000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["An update on the development of novel antifungal agents for eumycetoma"],"prefix":"10.3389","volume":"14","author":[{"given":"David J.","family":"Chandler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandro","family":"Bonifaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy W. J.","family":"van de Sande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01338-20","article-title":"Development and validation of an in vitro resazurin-based susceptibility assay against Madurella mycetomatis","volume":"65","author":"Abd Algaffar","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0928-8244(03)00096-8","article-title":"A murine model of Madurella mycetomatis eumycetoma","volume":"37","author":"Ahmed","year":"2003","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1128\/AAC.48.7.2742-2746.2004","article-title":"In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay","volume":"48","author":"Ahmed","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"B4","first-page":"2261","article-title":"Fungi causing eumycotic mycetoma","volume-title":"Manual of clinical microbiology","author":"Ahmed","year":"2019"},{"key":"B5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/mmy\/myu098","article-title":"In vitro antifungal susceptibility of coelomycete agents of black grain eumycetoma to eight antifungals","volume":"53","author":"Ahmed","year":"2015","journal-title":"Med. Mycol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"017233","DOI":"10.1128\/JCM.01723-17","article-title":"Nigrograna mackinnonii, not Trematosphaeria grisea (syn., Madurella grisea), is the main agent of black grain eumycetoma in Latin America","volume":"56","author":"Ahmed","year":"2018","journal-title":"J. Clin. Microbiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e2942","DOI":"10.1371\/journal.pntd.0002942","article-title":"Madurella mycetomatis is highly susceptible to ravuconazole","volume":"8","author":"Ahmed","year":"2014","journal-title":"PLoS Negl. Trop. Dis. [Internet]"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1128\/AAC.04487-14","article-title":"In vitro interaction of currently used azoles with terbinafine against Madurella mycetomatis","volume":"59","author":"Ahmed","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4103\/0377-4929.40433","article-title":"Incidence and changing pattern of mycetoma in Western Rajasthan","volume":"51","author":"Bakshi","year":"2008","journal-title":"Indian J. Pathol. Microbiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1093\/jac\/dkx177","article-title":"In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates","volume":"72","author":"Buil","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1080\/00362177485380331","article-title":"Attempts to induce mycetoma in monkeys and mice using Madurella mycetomi","volume":"12","author":"Cavanagh","year":"1974","journal-title":"Sabouraudia"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1128\/AAC.49.12.5136-5138.2005","article-title":"In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi","volume":"49","author":"Cuenca-Estrella","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/tmi.12871","article-title":"Combining two antifungal agents does not enhance survival of Galleria mellonella larvae infected with Madurella mycetomatis","volume":"22","author":"Eadie","year":"2017","journal-title":"Trop. Med. Int. Health"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0003488","DOI":"10.1371\/journal.pntd.0003488","article-title":"The in vitro antifungal activity of sudanese medicinal plants against Madurella mycetomatis, the eumycetoma major causative agent","volume":"9","author":"Elfadil","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"00083977","DOI":"10.1371\/journal.pntd.0008397","article-title":"The global distribution of actinomycetoma and eumycetoma","volume":"14","author":"Emery","year":"2020","journal-title":"PLoS Negl. Trop. Dis. [Internet]"},{"key":"B16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.clindermatol.2011.09.009","volume":"30","author":"Estrada","year":"2012","journal-title":"Eumycetoma. Clin. Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1128\/AAC.42.2.313","article-title":"In vitro activity of a new oral triazole, BMS-207147 (ER-30346)","volume":"42","author":"Fung-Tomc","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/jac\/dki287","article-title":"Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits","volume":"56","author":"Groll","year":"2005","journal-title":"J. Antimicrob. Chemother"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1093\/trstmh\/trab076","article-title":"Modelling the spatial distribution of mycetoma in Sudan","volume":"115","author":"Hassan","year":"2021","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e004129","DOI":"10.1136\/bmjopen-2013-004129","article-title":"Systematic analysis of funding awarded for mycology research to institutions in the UK, 1997-2010","volume":"4","author":"Head","year":"2014","journal-title":"BMJ Open"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e57774","DOI":"10.1371\/journal.pone.0057774","article-title":"A histopathological exploration of the Madurella mycetomatis grain","volume":"8","author":"Ibrahim","year":"2013","journal-title":"PLoS One"},{"key":"B22","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/mmy\/myx064","article-title":"Amphotericin B and terbinafine but not the azoles prolong survival in Galleria mellonella larvae infected with Madurella mycetomatis","volume":"56","author":"Kloezen","year":"2018","journal-title":"Med. Mycol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e0003926","DOI":"10.1371\/journal.pntd.0003926","article-title":"A Madurella mycetomatis grain model in Galleria mellonella larvae","volume":"9","author":"Kloezen","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0009488","DOI":"10.1371\/journal.pntd.0009488","article-title":"The synthetic synergistic cinnamon oil CIN-102 is active against Madurella mycetomatis, the most common causative agent of mycetoma","volume":"15","author":"Konings","year":"2021","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/jac\/dkz529","article-title":"Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim","volume":"75","author":"Lim","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myac003","article-title":"Inhibiting DHN- and DOPA-melanin biosynthesis pathway increased the therapeutic value of itraconazole in Madurella mycetomatis infected Galleria mellonella","volume":"60","author":"Lim","year":"2022","journal-title":"Med. Mycol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0006437","DOI":"10.1371\/journal.pntd.0006437","article-title":"Addressing the most neglected diseases through an open research model: The discovery of fenarimols as novel drug candidates for eumycetoma","volume":"12","author":"Lim","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e0010159","DOI":"10.1371\/journal.pntd.0010159","article-title":"Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma","volume":"16","author":"Lim","year":"2022","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/trstmh\/traa168","article-title":"Melanin production in coelomycetous agents of black grain eumycetoma","volume":"115","author":"Lim","year":"2021","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"B30","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/17460441.2022.2080195","article-title":"Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach","volume":"17","author":"Lim","year":"2022","journal-title":"Expert Opin. Drug Discov."},{"key":"B31","doi-asserted-by":"publisher","first-page":"6313","DOI":"10.2147\/IJN.S279192","article-title":"Nanomedicine strategies to enhance tumor drug penetration in pancreatic cancer","volume":"16","author":"Lu","year":"2021","journal-title":"Int. J. Nanomedicine"},{"key":"B32","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.medmal.2013.06.004","article-title":"Management of mycetomas in France","volume":"43","author":"Mattioni","year":"2013","journal-title":"Med. Mal. Infect."},{"key":"B33","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/0035-9203(62)90143-8","article-title":"Chemotherapy of maduromycosis. I. Preliminary experiments with diamidinodi-phenylamine dihydrochloride and amphotericin B in vivo and in vitro","volume":"56","author":"Murray","year":"1962","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"B34","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/0035-9203(60)90114-0","article-title":"Experimental infection of mice with Madurella mycetomi","volume":"54","author":"Murray","year":"1960","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"B35","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/myc.13442","article-title":"Eumycetoma causative agents are inhibited in vitro by luliconazole, lanoconazole and ravuconazole","volume":"65","author":"Nyuykonge","year":"2022","journal-title":"Mycoses"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/myc.13509","article-title":"Epidemiological cut-off values for itraconazole and ravuconazole for Madurella mycetomatis, the most common causative agent of mycetoma","volume":"65","author":"Nyuykonge","year":"2022","journal-title":"Mycoses"},{"key":"B37","doi-asserted-by":"crossref","first-page":"12809","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","volume":"113","author":"Oliver","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B38","unstructured":"OpenSourceMycetoma2023"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e0231871","DOI":"10.1371\/journal.pone.0231871","article-title":"Mycetoma epidemiology, diagnosis management, and outcome in three hospital centres in Senegal from 2008 to 2018","volume":"15","author":"Sow","year":"2020","journal-title":"PLoS One"},{"key":"B40","doi-asserted-by":"publisher","first-page":"108142","DOI":"10.1016\/j.exppara.2021.108142","article-title":"Higher oral efficacy of ravuconazole in self-nanoemulsifying systems in shorter treatment in experimental chagas disease","volume":"228","author":"Sp\u00f3sito","year":"2021","journal-title":"Exp. Parasitol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0924-8579(02)00273-x","article-title":"In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease","volume":"21","author":"Urbina","year":"2003","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1128\/AAC.01045-10","article-title":"In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine","volume":"55","author":"van Belkum","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.micinf.2007.05.015","article-title":"Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole","volume":"9","author":"van de Sande","year":"2007","journal-title":"Microbes Infect."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e2550","DOI":"10.1371\/journal.pntd.0002550","article-title":"Global burden of human mycetoma: A systematic review and meta-analysis","volume":"7","author":"van de Sande","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/trstmh\/traa184","article-title":"In vitro susceptibility testing for black grain eumycetoma causative agents","volume":"115","author":"van de Sande","year":"2021","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1128\/AAC.49.4.1364-1368.2005","article-title":"Testing of the in vitro susceptibilities of Madurella mycetomatis to six antifungal agents by using the Sensititre system in comparison with a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5- [(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay and a modified NCCLS method","volume":"49","author":"van de Sande","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1111\/bjd.14025","article-title":"Amphotericin B but not itraconazole is able to prevent grain formation in experimental Madurella mycetomatis mycetoma in mice","volume":"173","author":"van de Sande","year":"2015","journal-title":"Br. J. Dermatol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e0005007","DOI":"10.1371\/journal.pntd.0005007","article-title":"Predictors of post-operative mycetoma recurrence using machine-learning algorithms: The mycetoma research center experience","volume":"10","author":"Wadal","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B49","volume-title":"Ending the neglect to attain the sustainable development goals: A road map for neglected tropical diseases 2021\u20132030","year":"2020"},{"key":"B50","volume-title":"Results of the 2017 global WHO survey on mycetoma","year":"2018"},{"key":"B51","volume-title":"Sixty-ninth World Health assembly WHA69.21","year":"2016"},{"key":"B52","volume-title":"Tenth meeting of the strategic and technical advisory group on neglected tropical diseases","year":"2017"},{"key":"B53","volume-title":"WHO fungal priority pathogens list to guide research","year":"2022"},{"key":"B54","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.trstmh.2012.07.003","article-title":"Predictors of cure, amputation and follow-up dropout among patients with mycetoma seen at the Mycetoma Research Centre, University of Khartoum, Sudan","volume":"106","author":"Zein","year":"2012","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"B55","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1473-3099(15)00359-X","article-title":"Mycetoma: A unique neglected tropical disease","volume":"16","author":"Zijlstra","year":"2016","journal-title":"Lancet Infect. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1165273\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T05:13:53Z","timestamp":1684386833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1165273\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":55,"alternative-id":["10.3389\/fphar.2023.1165273"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1165273","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]},"article-number":"1165273"}}